Home Featured Page 122

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Webinar – Retreat or Clinic: Which Approach is Right for You?

Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out;...

Psychedelics Weekly – The Legalization of Medical MDMA & Psilocybin in...

Bright Minds Biosciences Announces Non-Executive Director Appointment

Numinus Expands Research Capabilities with new Phoenix Clinical Research Site

Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of...

PT390 – Vital Psychedelic Conversations

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug...

Numinus Wellness Announces Voting Results From its Annual General and Special...

First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial...

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.